TICKERNERD
Menu
SEERSEERHealthcare · Biotechnology

SEER Stock Forecast: Seer, Inc. (California) Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.03
+0.50% on the day

The 1 Wall Street analysts covering Seer, Inc. (California) hold a median 12-month price target of $4 — +97.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 71 of 100 as at 21 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$111.9M
Ticker Nerd rank
71 / 100
Median analyst target
$4.00
Analysts covering
1
Total return, dividends reinvested
1W
−2.4%
1M
−3.3%
YTD
+10.9%
1Y
−1.0%
From 52W high
−14.3%
From 52W low
+25.3%
$1.62
$2.37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SEER stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Seer, Inc. (California) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
71 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
93
Growth
85
Accruals
81
Size
74
Volatility
66
Momentum
59
Quality
55
Revisions
27
Value
19

Issuance (93): The share count has been shrinking and the company is not leaning on new borrowing.

Value (19): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SEER stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SEER, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.50$2.00$2.50$3.00$3.50$4.00Oct 25Jan 26Apr 26Jul 26SEERHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +97.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 May 2026Canaccord GenuityInitiatesBuy$4.00
4 May 2026Canaccord GenuityInitiatesBuy—
13 Aug 2024Morgan StanleyMaintainsEqual-Weight—
5 Mar 2024Morgan StanleyReinstatesEqual-Weight$7.00
21 Feb 2023Morgan StanleyMaintainsEqual-Weight—
4 Jan 2023B of A SecuritiesDowngradeUnderperform—
10 Nov 2022Morgan StanleyMaintainsEqual-Weight—
11 Aug 2022JP MorganDowngradeNeutral—
11 Aug 2022Morgan StanleyMaintainsEqual-Weight—
5 May 2022Morgan StanleyMaintainsEqual-Weight—
1 Mar 2022Morgan StanleyMaintainsEqual-Weight—
15 Feb 2022Morgan StanleyMaintainsEqual-Weight—
13 Aug 2021Morgan StanleyMaintainsEqual-Weight—
12 May 2021Morgan StanleyMaintainsEqual-Weight—
30 Mar 2021Morgan StanleyMaintainsEqual-Weight—
29 Dec 2020Cowen & Co.InitiatesOutperform—
29 Dec 2020JP MorganInitiatesOverweight—
29 Dec 2020Morgan StanleyInitiatesEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SEER appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SEER analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Seer, Inc. (California) (SEER) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.6×

Cheaper than 84% of US stocks

Price / sales
7.9×

Cheaper than 17% of US stocks

Price / book
0.5×

Cheaper than 85% of US stocks

EV / EBITDA
0.3×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
−23.4%

Higher than 10% of US stocks

Earnings growth (YoY)
−34.7%

Higher than 14% of US stocks

Gross margin
33.1%

Higher than 39% of US stocks

Operating margin
−542.9%

Higher than 7% of US stocks

Net margin
49.7%

Higher than 96% of US stocks

Returns & dividend
Return on equity
−26.4%

Higher than 28% of US stocks

Return on assets
−15.3%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SEER vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SEERSeer, Inc. (California)$111.9M
71
COYACoya Therapeutics, Inc.$114.2M
56
ENGNenGene Therapeutics, Inc.$114.9M
27
NTHINeOnc Technologies Holdings, Inc.$116.5M
20
RANIRani Therapeutics Holdings, Inc.$120.0M
64
NAUTNautilus Biotechnology, Inc.$121.3M
55
HURATuHURA Biosciences, Inc.$121.4M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Seer, Inc. (California) — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SEER news & analysis

Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers

Business Wire · 13 Aug 2026negative

Bradley L. Radoff and Michael Torok, who own approximately 7.7% of Seer, Inc.'s outstanding shares, issued an open letter to the company's Board of Directors calling on it to publicly acknowledge that Seer needs to be taken private and to disclose a timeline for evaluating the latest acquisition offers.

Why it matters — This signals shareholder pressure on Seer's board over a possible privatization, which could affect the company's strategic direction and valuation.

Seer Q2 Earnings Call Highlights

MarketBeat · 12 Aug 2026negative

Seer reported second-quarter revenue of $3.1 million, down from $4.1 million a year earlier but up from $2.8 million in the first quarter. The proteomics company cited continued pressure on academic and government funding and longer sales cycles among some commercial customers.

Why it matters — SEER watchers would care because the company's year-over-year revenue decline and ongoing funding headwinds and longer commercial sales cycles point to continued demand challenges.

Seer, Inc. (SEER) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Seer, Inc. held its Q2 2026 earnings call, and Seeking Alpha published a transcript of the discussion. The call covered the company's second-quarter financial results and operational highlights.

Why it matters — Earnings call transcripts provide investors and analysts with detailed insights into Seer's financial performance and management's strategic outlook.

Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook

GlobeNewsWire · 11 Aug 2026neutral

Seer, Inc. announced its financial results for the second quarter ended June 30, 2026, and reaffirmed its full-year 2026 outlook. The announcement was made via a press release on August 11, 2026.

Why it matters — SEER watchers would care because the company confirmed its quarterly financial performance and affirmed its full-year 2026 guidance.

Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference

GlobeNewsWire · 3 Aug 2026neutral

Seer, Inc. announced that it will participate in the Canaccord Genuity 46th Annual Growth Conference, which is scheduled to be held in Boston, MA. The company made the announcement on August 3, 2026.

Why it matters — The announcement signals that Seer will have a speaking or presentation opportunity at a major industry investment conference, giving investors a chance to hear updates directly from the company.

FAQ

Frequently asked questions about SEER stock

What is the SEER stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Seer, Inc. (California) have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SEER stock a buy right now?

Of the 1 analysts covering Seer, Inc. (California), 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seer, Inc. (California) 71 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SEER?

As at 21 Aug 2026, Seer, Inc. (California) ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (93 of 100).

Will SEER stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +97.0% from the last close, and Ticker Nerd's factor model ranks Seer, Inc. (California) 71 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SEER stock forecast for 2030?

No analyst covering Seer, Inc. (California) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SEER are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has SEER stock performed over the past year?

Seer, Inc. (California) returned -1.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Seer, Inc. (California) do?

Seer Inc. operates as a biotechnology company renowned for its expertise in developing innovative solutions for protein analysis.

What is the latest news on SEER?

The most recent item we track (Business Wire, 13 Aug 2026): "Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers". Bradley L. Radoff and Michael Torok, who own approximately 7.7% of Seer, Inc.'s outstanding shares, issued an open letter to the company's Board of Directors calling on it to publicly acknowledge that Seer needs to be taken private and to disclose a timeline for evaluating the latest acquisition offers.

Company

About Seer, Inc. (California).

Seer Inc. operates as a biotechnology company renowned for its expertise in developing innovative solutions for protein analysis. The core purpose of Seer is to advance scientific understanding by providing high-throughput and scalable tools to decode the proteome—the entire complement of proteins expressed by a cell, tissue, or organism. Seer’s Proteograph Product Suite significantly enhances biological research by enabling a detailed examination of protein dynamics, aiding in the development of personalized medicine and fostering breakthroughs in disease diagnostics and therapy. This cutting-edge technology is pivotal in the healthcare and pharmaceuticals sectors, where understanding proteomic profiles can lead to improved therapeutic outcomes and clinical insights. Founded to bridge the gap between genomics and proteomics, Seer Inc. plays a critical role in empowering researchers and clinicians to uncover new biomolecular insights, thereby expanding the capabilities of precision medicine. The company's contributions to the life sciences market are not only significant for scientific advancement but also for the commercialization of research into practical healthcare applications.

CEO Dr. Omid C. Farokhzad M.D., Ph.D. · 124 employees · United States · https://seer.bio